Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported equity transactions dated 11/29/2025. He exercised 93,750 restricted stock units (RSUs), which converted into the same number of common shares at an exercise price of $0, and then had 27,516 shares of common stock withheld at $0.0896 per share to cover tax obligations related to the RSU vesting.
After these transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and has an additional 6,684,640 shares held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership. He also continues to hold 187,500 RSUs, from a grant made on November 29, 2024, that are scheduled to vest in four equal installments between May 29, 2026 and November 29, 2027.
MariMed Inc. Chief Operating Officer Timothy Shaw reported equity transactions involving company stock. On 11/29/2025, 81,250 restricted stock units (RSUs) converted into the same number of MariMed common shares at an exercise price of $0, increasing his directly held shares. On the same date, 23,847 common shares were withheld by MariMed at a price of $0.0896 per share to cover tax obligations tied to the RSU vesting. After these transactions, Shaw directly owned 9,191,315 shares of common stock.
In addition, 2,000,000 MariMed shares are held indirectly through the Shaw Family Trust, an irrevocable trust for his children, for which his spouse is trustee and as to which he disclaims beneficial ownership. The RSUs that vested on November 29, 2025 were part of a grant made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.
MariMed (MRMD) President & CEO Jon R. Levine reported equity award activity. On November 7, 2025, 75,000 RSUs converted into common stock (Code M) at $0, and 22,013 shares were withheld to satisfy taxes (Code F) at $0.097.
Following these transactions, he holds 21,006,481 shares directly and 6,684,640 shares indirectly by the Jon Levine Family Trust. 150,000 RSUs remain outstanding, scheduled to vest in equal installments on May 7, 2026 and November 7, 2026.
MariMed Inc. (MRMD) reported Q3 2025 results. Revenue was $40,764,000 with gross profit of $16,363,000. The quarter showed a net loss of $2,941,000 as interest expense and a $2,759,000 tax provision offset operating income of $1,599,000. Adjusted EBITDA was $5,139,000.
Year to date, revenue totaled $118,176,000 with a net loss of $9,815,000. Cash and equivalents were $6,596,000, and net cash provided by operating activities was $4,266,000. Mortgages and notes payable totaled $73,186,000, including $56,324,000 under the CREM loan. Shares outstanding were 394,452,517 as of September 30, 2025; 395,073,625 were outstanding as of November 3, 2025.
The First State Compassion Center acquisition closed March 1, 2025 and contributed $3,900,000 of revenue and $2,400,000 of net income in Q3. In the quarter, 1,155,274 Series C preferred shares converted into 5,776,370 common shares. The company later announced an exit from Missouri operations effective October 28, 2025.
MariMed Inc. furnished a Form 8-K stating it issued a press release with financial results for the three- and nine-month periods ended September 30, 2025.
The press release is included as Exhibit 99.1 and, under Item 2.02 and General Instruction B.2, is furnished and not deemed filed under the Exchange Act.
MariMed (MRMD) insider update: Chief Operating Officer Timothy Shaw reported routine equity transactions on 10/27/2025. He converted 111,112 restricted stock units into common stock (Code M; price $0), then had 32,612 shares withheld to cover taxes (Code F) at $0.1579 per share. Following these transactions, Shaw beneficially owns 9,133,912 shares directly. He also has 2,000,000 shares held indirectly by the Shaw Family Trust. The RSUs were granted on October 27, 2022 and are now fully vested, with no unvested RSUs remaining under that grant.
MariMed (MRMD) reported an insider equity change by President and CEO Jon R. Levine. On 10/27/2025, 138,888 restricted stock units converted one-for-one into common shares. To cover taxes on the vesting, the issuer withheld 40,764 shares at a price of $0.1579 under a tax-withholding transaction.
After these transactions, Levine held 20,953,494 shares directly. In addition, 6,684,640 shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children; Levine disclaims beneficial ownership of those securities. The RSUs were originally granted on October 27, 2022, and there are no unvested RSUs remaining under that grant.
Marimed Inc. Chief Operating Officer Timothy Shaw reported transactions on 10/02/2025 showing receipt of 9,981 restricted stock units (RSUs) that convert one-for-one into common shares and the vesting-triggered withholding of 2,930 shares to satisfy taxes at $0.161 per share. After these transactions Mr. Shaw directly beneficially owns 9,055,412 shares and indirectly holds 2,000,000 shares through the irrevocable Shaw Family Trust, for a combined reported interest disclosed on the Form 4.
Jon R. Levine, who is listed as President and CEO, Director, and a 10% owner of Marimed Inc. (MRMD), reported transactions on 10/02/2025. 11,517 restricted stock units (RSUs) vested and were converted one-for-one into common shares; the filing shows an acquisition of 11,517 shares at a $0 price component and a separate disposition of 3,381 shares withheld by the issuer to satisfy tax-withholding obligations at a price of $0.161 per share. After these reported transactions, the filing lists 20,855,370 shares beneficially owned directly and 6,684,640 shares held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children (the reporting person disclaims beneficial ownership of the trust shares). The RSU grant referenced was originally awarded on April 2, 2024 and remaining installments vest in three equal parts on April 2, 2026, October 2, 2026, and April 2, 2027.
Mario Pinho, Chief Financial Officer of MARIMED INC. (MRMD), reported transactions dated 09/30/2025 related to restricted stock units (RSUs) granted earlier in 2025. On that date 53,572 RSUs were reported as acquired (Code M) and converted one-for-one into common stock, resulting in 53,571 shares beneficially owned from those RSUs. The issuer withheld 15,347 shares to satisfy tax withholding, recorded as a disposition at a price of $0.1635 per share, leaving the reporting person with 195,611 shares beneficially owned after the transactions. The RSUs were originally granted on February 17, 2025 and the remaining RSUs will vest on December 31, 2025 per the award agreement.